STARTUP PROFILE

CereGate

COUNTRY
Germany
FOUNDED
2019
CATEGORY
Neuromodulation
Developing a software-driven computer-brain interface platform that augments neuromodulation implants to enable communication and therapy personalization.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series A
MODALITY
Software
FORM FACTOR
Software/app
INTERFACE DEPTH
Software
INDICATION
Parkinson's
TARGET USER
Clinicians
REGULATORY STAGE
Investigational
CereGate sits in the emerging “software layer for implants” category, augmenting existing neuromodulation devices with communication and adaptive control capabilities rather than developing hardware itself. This platform approach allows it to piggyback on installed DBS infrastructure, though it is dependent on partnerships with device manufacturers for scale.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

CereGate closed an oversubscribed Series C led by an unnamed global US medtech company. The Munich-based company develops software that delivers personalized stimulation through existing deep brain stimulation implants, initially targeting freezing of gait in Parkinson's disease. Its software runs on Boston Scientific systems and has been tested in more than 85 participants. The funding amount was not disclosed.

Articles featuring
CereGate